A recent study in mice has shown promising results in potentially reversing diabetes with a two-drug combination that effectively regrows cells in the pancreas that produce insulin. The treatment, consisting of exendin-4 and harmine, increased the number of insulin-producing cells by up to 700% in just 3 months. While more research is needed, this discovery could offer a simple and scalable approach to diabetes treatment.
Beta cells in the pancreas are responsible for producing insulin, and in individuals with diabetes, these cells are reduced in number. Although current diabetes drugs are available, none help restore beta cells. Scientists have found that DYRK1A inhibitors can induce beta cell proliferation and differentiation, offering a potential solution to increase beta cell mass. The combination of harmine and exendin-4 has shown promising results in improving beta cell function and glycemic control in mice.
Research has shown that DYRK1A inhibitors may increase beta cell mass and improve blood supply to the islets of Langerhans, which could enhance insulin release and cell survival. The two-drug combination of harmine and exendin-4 has shown significant benefits in mice with both normal blood sugar control and severe diabetes, without hypoglycemia. These findings raise hope for future regenerative therapies to treat diabetes and potentially rescue patients with beta cell failure.
While the results are encouraging, further studies are needed to determine the effectiveness and safety of DYRK1A inhibitors in humans. Concerns about unintended effects on other organs and individual variations in response to treatment need to be addressed. Phase 1 clinical trials are currently underway to test the safety and tolerability of harmine and future DYRK1A inhibitors, with the goal of improving insulin levels in individuals with diabetes.
The potential of harmine as a natural product found in plants could make the drug combination relatively accessible once it reaches the market. Ongoing research is exploring the combination of beta cell regeneration inducers with immunomodulators to improve insulin levels in individuals with type 1 diabetes. If further studies confirm these findings, this innovative approach to diabetes treatment could be a significant breakthrough in addressing the epidemic of diabetes.
